Healthcare ran to an all-time high and led S&P sectors, XLV +2.4% on large-cap pharma strength with Lilly at a record; development-stage names went further, XBI +3.6%, NBI +3.2% and BBC +4.4% against RUT +1.7%. Rapport's pre-open RAP-219 readout gave back a 25%+ premarket gain after the open.

Money rotated out of tech into value and defensives: Dow +0.95% (~490 points), S&P +0.3%, NDX (0.1%), with GM (7.5%) on below-consensus guidance.

RAP-219, Rapport's oral TARPγ8-targeted AMPA modulator licensed from J&J, beat placebo by 3.1 points on the Young Mania Rating Scale at week 3 (15.4 vs 12.3) in a 253-patient Phase 2 acute bipolar mania study, p=0.045 per Stifel, with a significant secondary and no severe or serious adverse events; Rapport meets FDA in 1Q27 and plans two registrational trials from 2H27.

Why it matters: The win cleared significance but not Rapport's own bar: CEO Abe Ceesay had called 4 points the clinically meaningful threshold, and Stifel puts the competitive range at 3-4, so RAP-219 sits at the low end on efficacy. The pitch now shifts to tolerability, where adverse events ran at placebo-like rates and Jefferies calls safety clean, worth $1B+ to peak sales if it holds. Adherence decides share in bipolar, and AbbVie's Vraylar is tracking to $4.3B this year on four labels. Shares gave back a 25%+ premarket pop after the open. Open risks are maintenance and relapse data, plus the psychiatric-safety overhang carried by Fycompa, the AMPA comparator.

Source: Endpoints

More: Fierce Biotech; BioPharma Dive; BioSpace

Arcus' HIF-2α inhibitor casdatifan posted 35-month median OS and 13-month median PFS as monotherapy in 121 late-line clear cell RCC patients (52% with 3+ prior lines), 14.5-month median PFS with cabozantinib in second line (n=43) and 69% 12-month PFS with zimberelimab in first line (n=30) at an investor event; the Phase 3 PEAK-20 (with ipilimumab/nivolumab) starts by year-end and RCUS rose about 9.5%.

Why it matters: This is a cross-trial case against Merck's Welireg, the only approved HIF-2α inhibitor, and Arcus built the deck to make it: late-line PFS held flat across one to three prior TKI regimens, where Merck's LITESPARK-013 showed PFS falling as prior lines rose. The first-line doublet's 6.7% primary progression against roughly 30% for Keytruda alone is the number that sells a frontline plan, but n=30 at 11.5 months is thin and every comparator is historical. Gilead let its option lapse in early 2025, so Arcus runs PEAK-1, PEAK-20 and a tivozanib study largely alone, with Taiho holding Japan and most of Asia. The release reported no unexpected safety signals but did not break out anemia or hypoxia, the class's known liabilities.

Source: Urology Times

More: Arcus (Business Wire)

ICER's launch-price report on 26 drugs it reviewed that won approval in 2022-2025 found about two-thirds launched well above its $100K-$150K per QALY thresholds; the inflation-adjusted median net launch price rose from $190K to $257K, and nearly a quarter of drugs it evaluated in 2025 carried net prices above $500K.

Why it matters: The named drugs carry the read-through. ICER says Insmed's Brinsupri and Merck's Winrevair would each need roughly 90% discounts to hit its thresholds and Carvykti about a third, while Vertex's Journavx already clears and Casgevy at $2.2M needs only about 7%. ICER sets no prices, but payers use its numbers in coverage and step edits, and the report counts four in ten prescriptions for these drugs rejected, worse in Medicare. It lands with more than a dozen MFN-for-tariff-relief deals signed and IRA negotiation running, though BioPharma Dive notes neither has yet dented reported margins. Rare-disease and cell and gene launches, which pushed the 2025 median up, carry the most exposure.

Source: Endpoints

More: BioPharma Dive

Pfizer ended a Phase 2 study of PF-06835375 in primary immune thrombocytopenia, calling it a business decision and leaving the program's future open. — Fierce Biotech

Amgen and AstraZeneca's Tezspire posted 64.8% (210mg) and 68.9% (420mg) histologic remission vs 3.5% for placebo at week 24 in the Phase 3 CROSSING eosinophilic esophagitis study at UEG Week, with filings planned for a third indication against Dupixent. — Fierce Pharma

Cosette won FDA approval for a liquid formulation of Evoxac (cevimeline) for dry mouth in Sjögren’s disease. — Fierce Pharma

Samsung Biologics won temporary court relief from a strike threat covering most of its drug-substance manufacturing. — Fierce Pharma

OpenAI acquired Orchestra Bio, a platform that coordinates drug-development programs with AI agents, to fold into its Rosalind life-sciences suite; terms undisclosed. — Axios

Astellas partnered with AI Proteins, Chris Bahl's Boston miniprotein startup, on AI-designed miniprotein drugs; terms undisclosed. — Endpoints

No notable private financings since yesterday.

Lycia set IPO terms of 14.7M shares at $16-$18, about $228M net at the midpoint ($263M with the option), to take LCA-0061, a Phase 1 IgE-depleting cataLYTAC degrader for food allergy, through Phase 2. — Fierce Biotech

Disc Medicine (IRON) priced an upsized $450M follow-on, 6M shares at $75 (launched at $350M with pre-funded warrants) after Monday's APOLLO Phase 3 data; Jefferies, Leerink, Morgan Stanley and Cantor; closes 22 Oct. — GlobeNewswire

Genetic code expansion enabled plant-directed control of bacterial activity using the noncanonical amino acid O-methyl-L-tyrosine. — Nature Biotech